65,437 trials
Parkinson's Disease
Primary: Change in Average Adhesiveness Score of 2 Days of 24 Hours Patch Application as Rated by the Investigator (or Designee) Assessed According to the EMA Draft Guideline…
Endotracheal Intubation · Continuous IV Sedation · ICP Monitoring
Primary: Variability of Intracranial Pressure (ICP) — 5.66; 5.61 mmHg
Idiopathic Scoliosis · Spondylolisthesis
Primary: Morphine Equivalent Consumption (mg/kg) — 1.3; 1.36; 1.28; 1.275 mg/kg
Epilepsy · Post-traumatic Epilepsy
Primary: Post-Traumatic Epilepsy — 6; 8 participants
Head Injury
Primary: Glasgow Coma Scale (GCS) — 3.14; 3.11; 4.67 units on a scale
Nocturia
Primary: Part I: Change From Baseline in Mean Number of Nocturnal Voids at Week 4 — -0.86; -0.83; -1.00; -1.18 nocturnal voids — p=0.9303
Hypothermia
Primary: Maternal Hypothermia — 36.6; 36.4; 36.5; 36.3 Centigrades — p=<0.05
HIV Infections
Primary: Feasibility of Rapid HIV Testing in Emergency Department — 100 participants
Gastric Cancer
Primary: Overall Response Rate — 23 participants
Mental Illness
Primary: Time Till Employment in Days — 308; 301; 214 number of days to first employment — p=<0.05
Glabellar Frown Lines
Primary: Percentage of Subjects as Responders in the ILA (Using Validated 4-point Photographic Scale) and the SSA of Glabellar Lines at Maximum Frown — 0; 88.9; 91.4; 87.9…
Kinky Hair Syndrome
Primary: Gross Motor Development at 36 Mos of Age or at Death (Mos) — 13.743; 2.455; 15.667 Other - months
Irregular Menstrual Cycle
Primary: Number of Patients Received Dydrogesterone Therapy Cycles (by Cycle Number) — 1; 4; 269; 66 participants
Malignant Melanoma
Primary: Progression-free Survival — 9.90; 6.20; 12.30; 7.20 Months — p=0.0001
Hyperphosphatemia · Chronic Kidney Disease
Primary: AUC0-t of Candesartan — 1118; 826; 494; 759 ng*hr/mL